Vertaling van "treatment and retail prices of nrt or buproprion " (Frans → Nederlands) :

2001 € Costs include additional time spent by GP offering, prescribing and following-up pharmacological treatment and retail prices of NRT or Buproprion GP counselling occurs opportunistically during consultations for other diseases Counselling takes 10 minutes (range 5-15 minutes in sensitivity analysis).
2001 € Costs include additional time spent by GP offering, prescribing and following-up pharmacological treatment and retail prices of NRT or bupropion GP counselling occurs opportunistically during consultations for other diseases Counselling takes 10 minutes (range 5-15 minutes in sensitivity analysis).

Treatment (both NRT and Buproprion) lasts at least 1 month Retail price of NRT gum: not reported Retail price of NRT patch (3-month course): €354.54 (€, 2001) Retail price of NRT nasal spray (3-months course): €743.02 3% (range 0-5% in sensitivity analysis)
Treatment (both NRT and bupropion) lasts at least 1 month Retail price of NRT gum: not reported Retail price of NRT patch (3-month course): €354.54 (€, 2001) Retail price of NRT nasal spray (3-months course): €743.02 3% (range 0-5% in sensitivity analysis)

2000 US$ Average retail price of NRT gum (12-week course): US$218.78 Average retail price of NRT patch (8-week course): US$154.36 Average retail price of Buproprion (8-week course): US$201.39 Pharmacist time (5 hours of intervention, US$35/hr): US$175 Technician support (2 hours, US$5/hr): US$10 Material costs: US$5 0%
2000 US$ Average retail price of NRT gum (12-week course): US$218.78 Average retail price of NRT patch (8-week course): US$154.36 Average retail price of bupropion (8-week course): US$201.39 Pharmacist time (5 hours of intervention, US$35/hr): US$175 Technician support (2 hours, US$5/hr): US$10 Material costs: US$5 0%

Odds ratio of NRT versus control: 1.67 Odds ratio of Buproprion versus control: 2.1 Odds ratio of NRT+Buproprion versus control: 2.65 From these Odds Ratios and information on the control 12-month quit rate in the comparator intervention (0.04 for brief advice and 0.10 for counselling), the 12-month quit rate of treatment is calculated: treated quit rate for brief advice+NRT: 0.0650 treated quit rate for brief advice+Buproprion: 0.0805 treated quit rate for brief advice+Buproprion+NRT: 0.0994 treated quit rate for counselling+NRT: 0.1565 treated quit rate for counselling+Buproprion: 0.1892 treated quit rate for counselling+Buproprion+NRT: 0.2275 spontaneous cessation rate: 0.01. lifetime relapse rate: 40% (range 30-50%). number of LYG per quitter: 2 (range 1-3). number of QALYs gained per quitter: 2.7 (range 1.35-4.05) not reported The table gives an overview of the assumptions with respect to costs and effects (quit rates) in the average scenario.
Odds ratio of NRT versus control: 1.67 Odds ratio of bupropion versus control: 2.1 Odds ratio of NRT+bupropion versus control: 2.65 From these Odds Ratios and information on the control 12-month quit rate in the comparator intervention (0.04 for brief advice and 0.10 for counselling), the 12-month quit rate of treatment is calculated: treated quit rate for brief advice+NRT: 0.0650 treated quit rate for brief advice+bupropion: 0.0805 treated quit rate for brief advice+bupropion+NRT: 0.0994 treated quit rate for counselling+NRT: 0.1565 treated quit rate for counselling+bupropion: 0.1892 treated quit rate for counselling+bupropion+NRT: 0.2275 spontaneous cessation rate: 0.01. lifetime relapse rate: 40% (range 30-50%). number of LYG per quitter: 2 (range 1-3). number of QALYs gained per quitter: 2.7 (range 1.35-4.05) not reported The table gives an overview of the assumptions with respect to costs and effects (quit rates) in the average scenario.

Spontaneous cessation rate: 2.5% OR counselling only: 1.73 Incremental OR NRT gum (relative to counselling only): 1.63 Incremental OR NRT patch (relative to counselling only): 1.79 Incremental OR NRT spray (relative to counselling only): 2.35 Incremental OR NRT inhaler (relative to counselling only): 2.14 Incremental OR Buproprion (relative to counselling only): 2.30 % of smokers still under treatment after the first month: 50% (range 40-60% in sensitivity analysis) % of smokers still under treatment after the second month: 20% (range 15-25% in sensitivity analysis) Lifetime relapse probability after one year of abstinence: 35% (range 10-50% in sensitivity analysis) Effect of smoking cessation on mortality derived from the results of the American Cancer Society Prevention Study II. The mortality rate for former smokers was projected by calculating a weighted average of the incremental differentials between mortality rates of neversmokers and smokers, weighted according to the duration of abstinence.
Spontaneous cessation rate: 2.5% OR counselling only: 1.73 Incremental OR NRT gum (relative to counselling only): 1.63 Incremental OR NRT patch (relative to counselling only): 1.79 Incremental OR NRT spray (relative to counselling only): 2.35 Incremental OR NRT inhaler (relative to counselling only): 2.14 Incremental OR bupropion (relative to counselling only): 2.30 % of smokers still under treatment after the first month: 50% (range 40-60% in sensitivity analysis) % of smokers still under treatment after the second month: 20% (range 15-25% in sensitivity analysis) Lifetime relapse probability after one year of abstinence: 35% (range 10-50% in sensitivity analysis) Effect of smoking cessation on mortality derived from the results of the American Cancer Society Prevention Study II. The mortality rate for former smokers was projected by calculating a weighted average of the incremental differentials between mortality rates of neversmokers and smokers, weighted according to the duration of abstinence.

patients remain on one type of treatment throughout their smoking cessation therapy costs and consequences of side-effects of Buproprion or NRT were not taken into account
patients remain on one type of treatment throughout their smoking cessation therapy costs and consequences of side-effects of bupropion or NRT were not taken into account